The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2514530 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Xavier Sáez-Llorens und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Vacunación e Investigación - CEVAXIN, Panamá City, Panamá. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Public Health. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, AstraZeneca.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVE: New prophylaxis to reduce the burden of respiratory syncytial virus (RSV) disease are available, including a long-acting monoclonal antibody (nirsevimab) and maternal immunization with an RSV prefusion F protein vaccine (RSVpreF). We compared the potential public health impact of these strategies when implemented in Panama from the payer perspective. METHODS: A static model evaluated the use of year-round nirsevimab with/without catch-up, seasonal nirsevimab with catch-up, and RSVpreF in a birth cohort. Health, cost, quality-of-life outcomes, and the number needed to immunize (NNI) were compared to the current standard of care, followed by an indirect comparison of nirsevimab and RSVpreF. RESULTS: Seasonal nirsevimab with catch-up would be the most effective strategy as it would prevent 62% RSV-associated lower respiratory tract disease cases compared to RSVpreF, followed by year-round nirsevimab with catch-up that would prevent 46% of cases. Each of the nirsevimab strategies would have a greater impact on all outcomes compared to RSVpreF. The NNI to prevent an RSV infection and death was lower for the nirsevimab strategies compared to RSVpreF. CONCLUSION: RSV immunization strategies would significantly reduce the disease burden in Panama. Nirsevimab would have a greater public health impact than RSVpreF due to its sustained efficacy and protection regardless of gestational age. New strategies to prevent RSV in infants have become available, including a long-acting monoclonal antibody (nirsevimab) and maternal immunization with a bivalent respiratory syncytial virus (RSV) prefusion F protein (RSVpreF) vaccine, to reduce the burden of the associated disease in infants. We evaluated how these treatments could improve public health in Panama, a tropical country with year-round RSV circulation. This study modeled the new prevention strategies and compared them with the current standard of care (SoC) using palivizumab. Additionally, an indirect comparison was conducted between nirsevimab and RSVpreF to assess their health and economic impacts. As a result, we found that nirsevimab could prevent more RSV lower respiratory tract disease (LRTD) cases and reduce the associated costs compared to RSVpreF, resulting in a lower number of infants and mothers that need to be immunized to prevent RSV-associated disease. Both strategies would reduce the RSV-associated health and economic burdens in Panama, but the passive immunization strategy with nirsevimab is expected to generate a greater public health impact due to its sustained efficacy, programmatic aspects, and protection regardless of gestational age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Vacunación e Investigación - CEVAXIN, Panamá City, Panamá.
- Pediatric Infectious disease, Hospital del Niño Dr. José Renán Esquivel, Panamá City, Panamá.
- Sistema Nacional de Investigación at Secretaria Nacional de Ciencia y Tecnologia (SENACYT), Panama City, Panamá.
- Neuroeconomix, Bogotá, D.C, Colombia.
ORCID-Profile: Xavier Sáez-Llorens, Rodrigo DeAntonio
Förderung
- Sanofi
- AstraZeneca
Zitieren
APA
Sáez-Llorens, X., Lasalvia, P., Jaramillo, P., & DeAntonio, R. (2025). The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2514530
Vancouver
Sáez-Llorens X, Lasalvia P, Jaramillo P, DeAntonio R. The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2514530
BibTeX
@article{SezLlorens2025,
author = {Sáez-Llorens, Xavier and Lasalvia, Pieralessandro and Jaramillo, Paola and DeAntonio, Rodrigo},
title = {The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2514530}
}
EUVIMED